Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line

Liu,Ling; Li,Yang; Xiong,Xilin; Qi,Kai; Zhang,Chi; Fang,Jianpei; Guo,Haixia

doi:10.3892/ijo.2016.3756

Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line

Authors:
- Ling Liu
- Yang Li
- Xilin Xiong
- Kai Qi
- Chi Zhang
- Jianpei Fang
- Haixia Guo
View Affiliations

Affiliations: Department of Pediatric, Affiliated Hospital of Guangdong Medical University, Zhan Jiang, Guangdong 524000, P.R. China, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China
Published online on: November 3, 2016 https://doi.org/10.3892/ijo.2016.3756
Pages: 2319-2330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated arsenic trioxide (As2O3), cisplatin (DDP) and etoposide (Vp16) on the anticancer effects and P-glycoprotein (P-gp) expression in neuroblastoma (NB) SK-N-SH cells. The potential influence of As2O3, DDP and Vp16 currently included in NB routine treatment protocols on cytotoxicity in SK-N-SH cells was measured by flow cytometry and drug half-maximal inhibitory concentration (IC50) was established. Moreover, chemotherapeutic agent-mediated changes of cellular expression levels of resistant-related P-gp, was monitored using western blotting. The data showed that As2O3, DDP and Vp16 significantly inhibited the growth and survival of the SK-N-SH cells at different concentration. Notably, the levels of apoptosis were upregulated in SK-N-SH cells with an acceleration of the exposure time and the concentration of As2O3, DDP and Vp16. As2O3, DDP and Vp16 were observed with their IC50 values on SK-N-SH cells being 3 µM, 8 and 100 µg/ml, respectively. Flow cytometry analysis showed that As2O3 at low concentrations in SK-N-SH cells led to enhanced accumulation of cell populations in G2/M phase with increasing the exposure time, and increased levels of apoptosis. In contrast, we observed that SK-N-SH cell populations arrested in S phase by DDP and Vp16. In vitro examination revealed that following pretreatment of SK-N-SH cells with As2O3, the expression of P-gp was not increased. The expression of P-gp downregulation were noted following the group treated by As2O3 at 2 and 3 µM. Exposed to As2O3 at 3 µM for 72 h, SK-N-SH cells exhibited lower expression of P-gp than 2 µM As2O3 for 72 h. In contrast, the expression of P-gp was upregulated by DDP and VP16. In summary, SK-N-SH cells were responsive to chemotherapeutic agent-induced apoptosis in a dose-dependent and time-dependent manner. In particular, ours findings showed that low dose of As2O3 markedly reduced the P-gp expression and increased apoptotic cell death in human NB cell line.

View Figures

View References

1	Li T, Cui ZB, Ke XX, Tan J, Li FF, Li T, Wang XW and Cui HJ: Essential role for p53 and caspase-9 in DNA damaging drug-induced apoptosis in neuroblastoma IMR32 cells. DNA Cell Biol. 30:1045–1050. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wolter J, Angelini P and Irwin M: p53 family: Therapeutic targets in neuroblastoma. Future Oncol. 6:429–444. 2010. View Article : Google Scholar : PubMed/NCBI
3	Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et al; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol. 27:289–297. 2009. View Article : Google Scholar :
4	Sato Y, Kurosawa H, Sakamoto S, Kuwashima S, Hashimoto T, Okamoto K, Tsuchioka T, Fukushima K and Arisaka O: Usefulness of ¹⁸F-fluorodeoxyglucose positron emission tomography for follow-up of 13-cis-retinoic acid treatment for residual neuroblastoma after myeloablative chemotherapy. Medicine (Baltimore). 94:e12902015. View Article : Google Scholar
5	Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al; Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 363:1324–1334. 2010. View Article : Google Scholar : PubMed/NCBI
6	Lim JY, Kim YS, Kim KM, Min SJ and Kim Y: B-carotene inhibits neuroblastoma tumorigenesis by regulating cell differentiation and cancer cell stemness. Biochem Biophys Res Commun. 450:1475–1480. 2014. View Article : Google Scholar : PubMed/NCBI
7	Pettersson HM, Karlsson J, Pietras A, Øra I and Påhlman S: Arsenic trioxide and neuroblastoma cytotoxicity. J Bioenerg Biomembr. 39:35–41. 2007. View Article : Google Scholar : PubMed/NCBI
8	Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ and Reynolds CP: Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst. 99:1107–1119. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yonehara A, Tanaka Y, Kulkeaw K, Era T, Nakanishi Y and Sugiyama D: Aloe vera extract suppresses proliferation of neuroblastoma cells in vitro. Anticancer Res. 35:4479–4485. 2015.PubMed/NCBI
10	Goldsmith KC and Hogarty MD: Targeting programmed cell death pathways with experimental therapeutics: Opportunities in high-risk neuroblastoma. Cancer Lett. 228:133–141. 2005. View Article : Google Scholar : PubMed/NCBI
11	Street CA, Routhier AA, Spencer C, Perkins AL, Masterjohn K, Hackathorn A, Montalvo J, Dennstedt EA and Bryan BA: Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int J Oncol. 37:1297–1305. 2010.PubMed/NCBI
12	Qiu YY, Mirkin BL and Dwivedi RS: Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev. 29:456–463. 2005. View Article : Google Scholar : PubMed/NCBI
13	Pajic M, Norris MD, Cohn SL and Haber M: The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. Cancer Lett. 228:241–246. 2005. View Article : Google Scholar : PubMed/NCBI
14	Huang JM, Sheard MA, Ji L, Sposto R and Keshelava N: Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Mol Cancer Ther. 9:3289–3301. 2010. View Article : Google Scholar : PubMed/NCBI
15	Iwasaki I, Sugiyama H, Kanazawa S and Hemmi H: Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother Pharmacol. 49:438–444. 2002. View Article : Google Scholar : PubMed/NCBI
16	Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
17	Gesundheit B, Malach L, Or R and Hahn T: Neuroblastoma cell death is induced by inorganic arsenic trioxide (As (2)O (3)) and inhibited by a normal human bone marrow cell-derived factor. Cancer Microenviron. 1:153–157. 2008. View Article : Google Scholar
18	Au WY, Li CK, Lee V, Yuen HL, Yau J, Chan GC, Ha SY and Kwong YL: Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients. Pediatr Blood Cancer. 58:630–632. 2012. View Article : Google Scholar
19	Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, et al; Australasian Leukaemia and Lymphoma Group. All-transretinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 120:1570–1580; quiz 1752. 2012. View Article : Google Scholar
20	Haga N, Fujita N and Tsuruo T: Involvement of mitochondrial aggregation in arsenic trioxide (As₂O₃)-induced apoptosis in human glioblastoma cells. Cancer Sci. 96:825–833. 2005. View Article : Google Scholar : PubMed/NCBI
21	Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC and Påhlman S: Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther. 8:160–170. 2009. View Article : Google Scholar : PubMed/NCBI
22	Lallemand-Breitenbach V, Zhu J, Chen Z and de Thé H: Curing APL through PML/RARA degradation by As₂O₃. Trends Mol Med. 18:36–42. 2012. View Article : Google Scholar
23	Woo SY, Lee MY, Jung YJ, Yoo ES, Seoh JY, Shin HY, Ahn HS and Ryu KH: Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr Hematol Oncol. 23:231–243. 2006. View Article : Google Scholar : PubMed/NCBI
24	Kim DW, Ahan SH and Kim TY: Enhancement of arsenic trioxide (As(2)O(3))-mediated apoptosis using berberine in human neuroblastoma SH-SY5Y Cells. J Korean Neurosurg Soc. 42:392–399. 2007. View Article : Google Scholar
25	Florea AM, Splettstoesser F and Büsselberg D: Arsenic trioxide (As₂O₃) induced calcium signals and cytotoxicity in two human cell lines: SY-5Y neuroblastoma and 293 embryonic kidney (HEK). Toxicol Appl Pharmacol. 220:292–301. 2007. View Article : Google Scholar : PubMed/NCBI
26	Karlsson J, Edsjö A, Påhlman S and Pettersson HM: Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia. Mol Cancer Ther. 4:1128–1135. 2005. View Article : Google Scholar : PubMed/NCBI
27	Ryu KH, Woo SY, Lee MY, Jung YJ, Yoo ES, Seoh JY, Kie JH, Shin HY and Ahn HS: Morphological and biochemical changes induced by arsenic trioxide in neuroblastoma cell lines. Pediatr Hematol Oncol. 22:609–621. 2005. View Article : Google Scholar : PubMed/NCBI
28	Karlsson J, Øra I, Pörn-Ares I and Påhlman S: Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res. 10:3179–3188. 2004. View Article : Google Scholar : PubMed/NCBI
29	Qian XP, Liu BR, Yin HT, Wang LF, Zou ZY and Du J: Effect of arsenic trioxide on drug transporting molecules in acute promyelocytic leukemia cell line. Zhonghua Zhong Liu Za Zhi. 26:601–605. 2004.(In Chinese).
30	Lang WH and Sandoval JA: Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: A targeted approach for pathway analysis. J Biomol Screen. 19:1235–1245. 2014. View Article : Google Scholar : PubMed/NCBI
31	Zhao D, Jiang Y, Dong X, Liu Z, Qu B, Zhang Y, Ma N and Han Q: Arsenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms. Biomed Pharmacother. 65:354–358. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhao H, Guo W, Peng C, Ji T and Lu X: Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis. Mol Biol Rep. 37:2509–2515. 2010. View Article : Google Scholar
33	Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli V and Giuliani N: The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 39:55–65. 2011. View Article : Google Scholar
34	Xue YW, Han JG, Li BX and Yang BF: Reversal effect and mechanism of arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901. Yao Xue Xue Bao. 42:949–953. 2007.(In Chinese). PubMed/NCBI
35	Chan JY, Siu KP and Fung KP: Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells. Cancer Lett. 236:250–258. 2006. View Article : Google Scholar
36	Ling YH, Jiang JD, Holland JF and Perez-Soler R: Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol. 62:529–538. 2002. View Article : Google Scholar : PubMed/NCBI
37	Paffhausen T, Schwab M and Westermann F: Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett. 250:17–24. 2007. View Article : Google Scholar
38	Yin H, Tang SQ and Zhao QY: Effect of arsenic trioxide on MYCN mRNA expression in neuroblastoma cells. Shandong Med J. 37:57–58. 2008.
39	D’Aguanno S, D’Alessandro A, Pieroni L, Roveri A, Zaccarin M, Marzano V, De Canio M, Bernardini S, Federici G and Urbani A: New insights into neuroblastoma cisplatin resistance: A comparative proteomic and meta-mining investigation. J Proteome Res. 10:416–428. 2011. View Article : Google Scholar
40	Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
41	Park JW, Choi YJ, Jang MA, Baek SH, Lim JH, Passaniti T and Kwon TK: Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun. 286:726–734. 2001. View Article : Google Scholar : PubMed/NCBI
42	Gao F, Yi J, Yuan JQ, Shi GY and Tang XM: The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. Cell Res. 14:81–85. 2004. View Article : Google Scholar : PubMed/NCBI
43	Hassani S, Ghaffari SH, Zaker F, Mirzaee R, Mardani H, Bashash D, Zekri A, Yousefi M, Zaghal A, Alimoghaddam K, et al: Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. Ann Hematol. 92:1207–1220. 2013. View Article : Google Scholar : PubMed/NCBI
44	Han YH, Kim SZ, Kim SH and Park WH: Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett. 270:40–55. 2008. View Article : Google Scholar : PubMed/NCBI
45	Kandasamy K and Srivastava RK: Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. 62:4929–4937. 2002.PubMed/NCBI
46	Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N and Srivastava RK: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene. 20:6073–6083. 2001. View Article : Google Scholar : PubMed/NCBI
47	Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009. View Article : Google Scholar :
48	Zhang X, Jia S, Yang S and Yang Y, Yang T and Yang Y: Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. J Cell Biochem. 113:3528–3535. 2012. View Article : Google Scholar : PubMed/NCBI
49	Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y, Hu X, Hou K and Liu Y: Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 284:208–215. 2009. View Article : Google Scholar : PubMed/NCBI
50	Li YM and Broome JD: Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 59:776–780. 1999.PubMed/NCBI
51	Liu Q, Hilsenbeck S and Gazitt Y: Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. 101:4078–4087. 2003. View Article : Google Scholar : PubMed/NCBI
52	Wei N, Sun H, Wang F and Liu G: H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein. Cancer Chemother Pharmacol. 67:1017–1025. 2011. View Article : Google Scholar
53	Gibalová L, Sereš M, Rusnák A, Ditte P, Labudová M, Uhrík B, Pastorek J, Sedlák J, Breier A and Sulová Z: P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. Toxicol In Vitro. 26:435–444. 2012. View Article : Google Scholar : PubMed/NCBI
54	Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12:530–542. 1994. View Article : Google Scholar : PubMed/NCBI
55	Burg D, Riepsaame J, Pont C, Mulder G and van de Water B: Peptide-bond modified glutathione conjugate analogs modulate GSTpi function in GSH-conjugation, drug sensitivity and JNK signaling. Biochem Pharmacol. 71:268–277. 2006. View Article : Google Scholar
56	Lee WK, Torchalski B, Kohistani N and Thévenod F: ABCB1 protects kidney proximal tubule cells against cadmium-induced apoptosis: Roles of cadmium and ceramide transport. Toxicol Sci. 121:343–356. 2011. View Article : Google Scholar : PubMed/NCBI
57	Zhang X, Wu X, Li J, Sun Y, Gao P, Zhang C, Zhang H and Zhou G: MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells. J Surg Oncol. 104:466–471. 2011. View Article : Google Scholar : PubMed/NCBI
58	Duraj J, Zazrivcova K, Bodo J, Sulikova M and Sedlak J: Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma. 52:273–279. 2005.PubMed/NCBI
59	Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB and Unate H: Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene. 21:1945–1954. 2002. View Article : Google Scholar : PubMed/NCBI
60	Zhou J, Liu M, Aneja R, Chandra R, Lage H and Joshi HC: Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res. 66:445–452. 2006. View Article : Google Scholar : PubMed/NCBI
61	Gu J, Tang Y, Liu Y, Guo H, Wang Y, Cai L, Li Y and Wang B: Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo. Cancer Lett. 343:200–209. 2014. View Article : Google Scholar
62	Yang X and Pagé M: P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol Res. 7:619–624. 1995.PubMed/NCBI